Quanta Dialysis Technologies

The company's core product is the Quanta Dialysis System, formerly known as SC+. It is a compact, lightweight, and portable hemodialysis machine designed for use in a variety of settings, including hospitals, clinics, and patients' homes. The system is engineered for ease of use, featuring a simple user interface and a cartridge-based design that eliminates the need for chemical disinfection between treatments. It delivers performance and dose equivalents comparable to larger, traditional dialysis machines and supports high dialysate flow rates. A key feature is its versatility, allowing for different treatment schedules, from conventional three-times-a-week sessions to more frequent home-based therapies.

Quanta's business model involves direct sales of its dialysis system to healthcare facilities, including hospitals and dialysis clinics. The company has received significant venture capital funding to scale its operations, particularly in the United States. A major milestone was achieved with the U.S. Food and Drug Administration (FDA) 510(k) clearance for the system's use in acute and chronic care facilities in 2020. In 2024, Quanta received an additional FDA clearance for home hemodialysis use, which significantly expanded its target market to include the home healthcare sector. The company's revenue is generated from the sale of the dialysis machines and the associated disposable cartridges.

The company has also developed a cloud-based digital health platform to complement its device. This platform enables remote monitoring by clinicians and automates data capture and reporting, streamlining the treatment process. Keywords: hemodialysis system, portable dialysis, kidney care, medical device, home dialysis, renal care, FDA clearance, dialysis technology, acute care, chronic care